ShanX MedTech has been awarded an EU4Health contract to lead a European joint tender developing a rapid point-of-care (POC) antimicrobial susceptibility test (AST), a critical step in the fight against antimicrobial resistance (AMR).

This highly competitive call for tenders, launched by DG HERA and HaDEA, marks the first EU procurement dedicated to rapid POC AST, accelerating innovation toward a regulatory-ready diagnostic that delivers actionable results when and where they matter most: close to the patient.